Current guidelines allow testing for patients diagnosed with TNBC at ≤60 years of age with or without a significant family history of breast cancer [72]. BRCA1 and BRCA2 testing in 439 women with TNBC from the Australian Breast Cancer Tissue Bank supports TNBC pathology as a sufficient criterion for testing as 59% of women with pathogenic mutations did not have a family history of breast or ovarian cancer [34]. Here, BRCA1 is linked to ovarian cancer.